Table 3.
Characteristics of included PRO publications and their PRO data collection methods (n = 21)a
| PRO characteristic | No. (%) |
|---|---|
| PRO publication year | |
| 2019 | 3 (14.3) |
| 2018 | 4 (19.0) |
| 2017 | 10 (47.6) |
| 2016 | 2 (9.5) |
| 2012 | 1 (4.8) |
| 2009 | 1 (4.8) |
| Journal impact factor at time of publication | |
| <10 | 5 (23.8) |
| 10-20 | 3 (14.3) |
| >20 | 13 (61.9) |
| PRO stated as an endpoint | |
| Primary endpoint | 0 |
| Secondary endpoint | 9 (42.9) |
| Exploratory endpoint | 10 (47.6) |
| Unclear | 2 (9.5) |
| PRO hypothesis | |
| Specific | 4 (19.0) |
| Broad | 12 (57.1) |
| Not reported | 5 (23.8) |
| PRO instruments | |
| PRO instruments used | |
| EQ-5D | 17 (81.0) |
| EORTC QLQ-C30 | 14 (66.7) |
| EORTC QLQ-LC13 | 4 (19.0) |
| LCSS | 2 (9.5) |
| IFN-specific symptom checklist | 1 (4.8) |
| FKSI-DRS | 1 (4.8) |
| FACT-G | 1 (4.8) |
| FACT-M | 1 (4.8) |
| FKSI-19 | 1 (4.8) |
| PedsQL | 1 (4.8) |
| QLQ-H&N35 | 1 (4.8) |
| Site-specific PRO instrument | 9 (42.9) |
| Reference of the PRO instrument provided | 18 (85.7) |
| Data collection | |
| PRO collection method | |
| Electronic | 10 (47.6) |
| Paper | 6 (28.6) |
| Not reported | 5 (23.8) |
| Time point assessment | |
| Baseline time point collected | 21 (100) |
| Two or more follow-up time points collected | 21 (100) |
aEORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-core questionnaire; EORTC QLQ-LC13 = EORTC QLQ-Lung Cancer Module; EQ-5D = EuroQol-5D; FACT-G = Functional Assessment of Cancer Therapy: General; FACT-M = FACT-Melanoma; FKSI-19 = Functional Assessment of Cancer Therapy – Kidney Symptom Index; FKSI-DRS = Functional Assessment of Cancer Therapy – Kidney Symptom Index—Disease Related Symptoms; IFN = interferon; LCSS = Lung Cancer Symptom Scale; PedsQL = Pediatric Quality of Life Inventory; PRO = patient-reported outcome; QLQ-H&N35 = Quality of Life Questionnaire Head and Neck Cancer Module.